The only FDA-approved therapy proven to reduce delusions and hallucinations associated with PD in elderly patients without impacting motor function1,2*
NUPLAZID 34 mg showed continuous improvement over 6 weeks
Results from a Phase 3, randomized, multicenter, double-blind, placebo-controlled, parallel-group study of PD psychosis patients (N=199).1,2 Primary endpoint was change from baseline at 6 weeks in the 9-item SAPS-PD. Doses of PD medications taken prior to baseline were required to be stable 30 days prior to study start and throughout the study period. Mean baseline score was 15.9 for NUPLAZID and 14.7 for placebo. The mean age of patients enrolled in the clinical study with NUPLAZID was 72 years.2 While the primary endpoint was designed to measure change from baseline to Week 6, a statistically significant difference between NUPLAZID and placebo was observed at Week 4 (P=0.0369) and again at Week 6 (P=0.0014).
LSM=least-squares mean; SAPS-PD=Scale for Assessment of Positive Symptoms-Parkinson's Disease; SE=standard error.
*As measured by Unified Disease Rating Scale Parts II and III (UPDRS II + III).
Limit PD psychosis, not your patients
UPDRS II+III is a clinical rating scale that assesses motor function and its impact on activities of daily living
The UPDRS score was calculated as the sum of the 40 items from activities of daily living and motor examination, with a range of 0 to 160
A negative change in score indicates improvement
*As measured by Unified Parkinson's Disease Rating Scale Parts II and III (UPDRS II+III).
†Difference (drug minus placebo) in LSM.
‡Noninferiority criteria required that the upper bound of the 95% CI not exceed 5.
CI=confidence interval; LSM=least-squares mean.